PS2 mRNA expression adds prognostic information to node status for 6-year survival in breast cancer
1998

pS2 mRNA Expression and Breast Cancer Survival

Sample size: 90 publication Evidence: moderate

Author Information

Author(s): AM Thompson, RA Elton, RA Hawkins, U Chetty, CM Steel

Primary Institution: Ninewells Hospital and Medical School

Hypothesis

Can pS2 mRNA expression provide additional prognostic information for breast cancer survival?

Conclusion

pS2 mRNA expression is associated with better survival outcomes in breast cancer patients over a minimum of 6 years.

Supporting Evidence

  • pS2 mRNA expression was present in 29% of cancers studied.
  • Patients with pS2 expression had no mortality at 6 years if node negative.
  • Node positive patients with pS2 negative had a 41% mortality at 6 years.
  • pS2 expression was significantly associated with freedom from disease recurrence.

Takeaway

This study found that a specific gene, pS2, can help doctors predict how well breast cancer patients will do over time.

Methodology

Northern blotting was used to detect pS2 mRNA in tumor tissue from 90 breast cancer patients, with follow-up for at least 6 years.

Limitations

The study did not assess tumor grade and progesterone receptor status.

Participant Demographics

90 female patients with invasive breast cancer, mean age 56 years.

Statistical Information

P-Value

0.026

Confidence Interval

1.24-12.3

Statistical Significance

p<0.001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication